Slide 1: Corporate Update
Corporate Update August 13, 2026
Slide 2: Legal Notices
Legal Notices The information in this slide deck is current as of August 13, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information her
Slide 3: Unique Capabilities to Develop Next Generation Antibodies for Treating Cancer
Unique Capabilities to Develop Next Generation Antibodies for Treating Cancer Novel Platform Technologies Support Pipeline Proprietary DART® Platforms: TRIDENT® ADCs Dual Checkpoints TCEs Broad Clinical Pipeline & Track Record of Advancing Novel Medicines ` Innovative Antibody-Based 4 Clinical-Stage
Slide 4: Innovative Product Pipeline with Significant Rights Retained
Innovative Product Pipeline with Significant Rights Retained Phase 1 Phase 1/2 Phase 2/3 Program Target / Modality Lead Indication(s) Preclinical Partner Dose Finding PoC Pivotal Antibody Drug Conjugates SCCHN, Endometrial, MGC026 B7-H3 / TOP1i — Melanoma, Sarcoma MGC028 ADAM9 / TOP1i Solid Tumors —
Slide 5: MGC026: Future Development Opportunity
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC026: Future Development Opportunity Presentation of full dose escalation and preliminary cohort expansion results at ESMO 2026 • Significant market interest in B7-H3-targeting ADCs Significant Market Multiple major pharma partnerships announced Interest
Slide 6: MGC026: Designed as Potential Best-in-Class B7-H3 ADC
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC026: Designed as Potential Best-in-Class B7-H3 ADC B7-H3 Expressed on Tumor Cells, Evidence of Clinical Activity Established by Tumor-associated Stroma and Vasculature Other B7-H3 ADCs Across Multiple Cancers Unique B7-H3 Antibody MGC026 Head & Neck Sarcom
Slide 7: We Believe MGC026 is Well Positioned Among Competing Molecules
MGC026 MGC028 MGC030 Lorigerlimab MGD024 We Believe MGC026 is Well Positioned Among Competing Molecules(1) Furthest Ifinatamab Deruxtecan Risvutatug Rezetecan DB-1311/ Advanced (I-DXd, DS-7300) (HS-20093/GSK5764227) YL201 BNT345 MGC026 B7-H3 ADCs: Company/ Partner Tumor micro- GGFG Tetrapeptide Tetr
Slide 8: MGC026 Phase 1 First-in-Human Study: Dose Escalation Followed by Expansion
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC026 Phase 1 First-in-Human Study: Dose Escalation Followed by Expansion Study Design Phase 1a (N=32 Enrolled) Tumor-Specific Cohorts (N=42 Enrolled) Cohort 6 SCCHN (Simon’s 2-stage design) Key Inclusion Criteria N=22 12 mg/kg Threshold met N=18 Locally a
Slide 9: Significant Unmet Need Across Multiple Segments of SCCHN
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Significant Unmet Need Across Multiple Segments of SCCHN Standard of Care for Metastatic SCCHN (NCCN Preferred) Unmet Needs PD-L1 Positive PD-L1 Negative • Poor response rate and durability of response(3) 1L CPS ≥ 1 (~80%)(1) CPS < 1 (~20%) (1) ‒ Pembro monot
Slide 10: Enhanced MGC026 Anti-tumor Activity in Combination with CPI in Preclinical Models
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Enhanced MGC026 Anti-tumor Activity in Combination with CPI in Preclincal Models ADC and checkpoint inhibitor (CPI) leverage complementary MoA’s to enhance anti-tumor activity MC38-huB7-H3 (Murine Colorectal Cancer)(1) 3500 Mean Tumor Volume (mm3) 3000 Tumor
Slide 11: MGC028: Potential First-in-Class ADAM9 ADC
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC028: Potential First-in-Class ADAM9 ADC Attractive ADC Target ADAM9 Favorable Preclinical Data • ADAM9 (A Disintegrin And • Potent anti-tumor activity observed in Metalloprotease 9) multiple in vivo PDX models ‒ Plays role in tumorigenesis • Tolerated in G
Slide 12: MGC028: Preclinical Profile Supports Broad Development Opportunity
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC028: Preclinical Profile Supports Broad Development Opportunity Potent Activity Observed Across PDX Models ADAM9 Expression by Tumor Type (IHC)(1) with Range of ADAM9 Expression Colorectal Cancer 100% 3% H-score = 87 Pancreatic Cancer H-score = 116 6% 13%
Slide 13: MGC030: Potential First-in-Class ADC
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGC030: Potential First-in-Class ADC Binds to Novel Target TBA Favorable Preclinical Data • Targets undisclosed antigen expressed • Encouraging safety and tolerability across several solid tumors profile in GLP tox study • No approved therapeutics to this • P
Slide 14: Lorigerlimab (PD-1 × CTLA-4): DART Molecule with Two Validated Checkpoint Targets
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Lorigerlimab (PD-1 × CTLA-4): DART Molecule with Two Validated Checkpoint Targets Dual Checkpoint Blockade CTLA-4 Advancing Development in CCGC • Maintains PD-1 inhibition of PD-1 • Initial LINNET CCGC cohort data: mAbs on all PD-1pos cells ‒ 25% ORR (4/16 ev
Slide 15: Lorigerlimab Demonstrated Superior in Vivo Checkpoint Blockade vs. Volrustomig
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Lorigerlimab Demonstrated Superior in Vivo Checkpoint Blockade vs. Volrustomig Superior PD-L1 Blockade on PD-1Pos Cells Enhanced CTLA-4 Blockade on PD-1pos / CTLA-4pos Cells PD-1 Reporter Assay Jurkat CTLA-4 Jurkat PD-1/CTLA-4 8000 400 250 6000 B7-1 binding,
Slide 16: Clear Cell Gynecologic Cancer Patients Need Better Treatment Options
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Clear Cell Gynecologic Cancer Patients Need Better Treatment Options Unmet Needs Associated with Clear Cell Gyn Cancers(1) Ovarian Cancer Segmentation Mucinous Poor Disease • CCGC characteristically chemo-resistant (9% Carcinoma Control with ORR and 2.6 mos.
Slide 17: Lorigerlimab: PROC and CCGC Phase 2 Study Design Summary
MGC026 MGC028 MGC030 Lorigerlimab MGD024 Lorigerlimab: PROC and CCGC Phase 2 Study Design Summary Plan to enroll 20 add’l CCGC patients at 3 mg/kg Q3W, with plan to update study results in 1H2027 Platinum-Resistant Ovarian Cancer (PROC) (Discontinued) Lorigerlimab Cohort 6 mg/kg Q3W 1 N=24 Primary E
Slide 18: MGD024: CD123 × CD3 DART Molecule (Subject to Exclusive Option with Gilead)
MGC026 MGC028 MGC030 Lorigerlimab MGD024 MGD024: CD123 × CD3 DART Molecule (Subject to Exclusive Option with Gilead) CD123 is Key Leukemia Target CD3 Favorable Preclinical Data • Redirected T-cell killing against • Anti-leukemic activity in vitro leukemia cells and in murine tumor models CD123 • Nex
Slide 19: Multiple Potential 2026 Catalysts to Drive Shareholder Value
Multiple Potential 2026 Catalysts to Drive Shareholder Value Advance MGC026 and MGC028 Complete IND application Determine development path to assess clinical PoC for MGC030 for lorigerlimab Initial MGC026 data (ESMO 2026) IND submission Interim LINNET data poster (ESMO 2026) Initial MGC028 data (lat
Slide 20: Well Resourced to Execute on Strategic Priorities
Well Resourced to Execute on Strategic Priorities Historical Financial Details 6 Mos. Ended June 30, $ in Millions 2022 2023 2024 2025 2025 2026 Total Revenues $152 $59(1) $150 $150 $14 $40 R&D Expense 207 167 177 147 80 74 Total Costs and Expenses 273 227 261 222 101 91 Cash & Investments 154 230 2
Slide 21: Thank You!
Thank You! Investor Relations Inquiries Jim Karrels – SVP, Chief Financial Officer karrelsj@macrogenics.com Argot Partners macrogenics@argotpartners.com Business Development Inquiries Harish Krishnaswamy – SVP, Business Development & Portfolio Planning krishnaswamyh@macrogenics.com www.macrogenics.c